[{"id":"79649cc6-d582-4cf7-94a7-6b84b6103cab","acronym":"","url":"https://clinicaltrials.gov/study/NCT04901702","created_at":"2021-05-25T18:52:49.387Z","updated_at":"2025-02-25T12:28:07.986Z","phase":"Phase 1/2","brief_title":"Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma","source_id_and_acronym":"NCT04901702","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" EWSR1 • FLI1","pipe":"","alterations":" ","tags":["EWSR1 • FLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Talzenna (talazoparib) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 06/09/2021","start_date":" 06/09/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"9a0a8faa-2764-48be-bddc-53cde9f97223","acronym":"LiFFT","url":"https://clinicaltrials.gov/study/NCT05918640","created_at":"2023-06-26T14:09:13.345Z","updated_at":"2025-02-25T15:13:34.219Z","phase":"Phase 1/2","brief_title":"Lurbinectedin in FET-Fused Tumors","source_id_and_acronym":"NCT05918640 - LiFFT","lead_sponsor":"Children's Hospital of Philadelphia","biomarkers":" EWSR1 • ETV1 • FLI1 • FUS • TAF15 • ETV4","pipe":"","alterations":" ","tags":["EWSR1 • ETV1 • FLI1 • FUS • TAF15 • ETV4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepzelca (lurbinectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 07/27/2023","start_date":" 07/27/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2028","study_completion_date":" 07/30/2028","last_update_posted":"2025-02-13"},{"id":"1079f78e-9ce0-445a-837c-c2dc7bc96947","acronym":"","url":"https://clinicaltrials.gov/study/NCT05275426","created_at":"2022-03-11T15:53:40.436Z","updated_at":"2024-07-02T16:35:13.985Z","phase":"Phase 2","brief_title":"A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor","source_id_and_acronym":"NCT05275426","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" WT1 • BCOR • EWSR1 • ETV1 • FLI1 • ETV4","pipe":" | ","alterations":" EWSR1-WT1 fusion","tags":["WT1 • BCOR • EWSR1 • ETV1 • FLI1 • ETV4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EWSR1-WT1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • ESP-01"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/02/2022","start_date":" 03/02/2022","primary_txt":" Primary completion: 03/02/2025","primary_completion_date":" 03/02/2025","study_txt":" Completion: 03/02/2025","study_completion_date":" 03/02/2025","last_update_posted":"2024-03-19"},{"id":"73b9aa98-7882-4ef9-8648-1da0dc4ba8a9","acronym":"SARC037","url":"https://clinicaltrials.gov/study/NCT04067115","created_at":"2021-01-18T19:55:32.138Z","updated_at":"2024-07-02T16:35:25.576Z","phase":"Phase 1/2","brief_title":"SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients","source_id_and_acronym":"NCT04067115 - SARC037","lead_sponsor":"Sarcoma Alliance for Research through Collaboration","biomarkers":" EWSR1 • FLI1","pipe":"","alterations":" ","tags":["EWSR1 • FLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • Yondelis (trabectedin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 01/05/2021","start_date":" 01/05/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-12-21"},{"id":"2eee3991-cdd2-46bf-8242-9a9230dc239a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04661852","created_at":"2021-01-19T20:43:03.275Z","updated_at":"2024-07-02T16:35:55.515Z","phase":"Phase 1","brief_title":"Cabozantinib With Topotecan-Cyclophosphamide","source_id_and_acronym":"NCT04661852","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" EWSR1 • FLI1 • FUS","pipe":"","alterations":" ","tags":["EWSR1 • FLI1 • FUS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • cyclophosphamide • Cometriq (cabozantinib capsule) • topotecan • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 12/23/2020","start_date":" 12/23/2020","primary_txt":" Primary completion: 10/24/2022","primary_completion_date":" 10/24/2022","study_txt":" Completion: 10/24/2022","study_completion_date":" 10/24/2022","last_update_posted":"2023-02-15"},{"id":"310e631e-b071-40b1-a519-01d9a5329dbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04129151","created_at":"2021-01-18T20:10:20.167Z","updated_at":"2024-07-02T16:35:55.610Z","phase":"Phase 2","brief_title":"Palbociclib + Ganitumab In Ewing Sarcoma","source_id_and_acronym":"NCT04129151","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CDK4 • EWSR1 • IGF1 • FLI1 • FUS","pipe":"","alterations":" ","tags":["CDK4 • EWSR1 • IGF1 • FLI1 • FUS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • ganitumab (AMG 479)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 12/05/2019","start_date":" 12/05/2019","primary_txt":" Primary completion: 12/15/2022","primary_completion_date":" 12/15/2022","study_txt":" Completion: 12/15/2022","study_completion_date":" 12/15/2022","last_update_posted":"2023-02-14"},{"id":"b9646e03-3b93-41fe-a534-1decec5bf67f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05042934","created_at":"2021-09-13T14:56:00.294Z","updated_at":"2024-07-02T16:36:17.321Z","phase":"Phase 1b/2","brief_title":"Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma","source_id_and_acronym":"NCT05042934","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EWSR1 • FLI1 • WRN • RECQL","pipe":"","alterations":" ","tags":["EWSR1 • FLI1 • WRN • RECQL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • Zepzelca (lurbinectedin)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/15/2021","start_date":" 09/15/2021","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 08/30/2022","study_completion_date":" 08/30/2022","last_update_posted":"2022-02-10"}]